Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05355272 · ClinicalTrials.gov registry record · Phase 2

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

A Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency, sponsored by Baylor College of Medicine.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
2
Study locations

NCT05355272 is a Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 20 participants, below the 132-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05355272, a Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency, is actively recruiting participants, sponsored by Baylor College of Medicine.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency? 2. Do the results of the study suggest there is merit in pursuing a larger trial to examine the efficacy of growth hormone as a treatment for growth hormone deficiency among veterans with Gulf War Illness? To determine eligibility for the study, veterans will be asked to complete several assessments including questionnaires, blood tests, and a scan of the brain. Participants who qualify for the study will receive recombinant human growth hormone for 6-months. A body composition scan will be performed at Day1, Day 90, and Day 180 of the intervention. Questionnaires and cognitive tests will also be collected before and after the trial.

Conditions Studied

Gulf War Syndrome Adult Growth Hormone Deficiency

Interventions

  • DRUG Recombinant human growth hormone

Study Locations (2)

Texas

  • Michael E. DeBakey VA Medical Center - Houston

Washington

  • VA Puget Sound Healthcare System - Seattle

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-03-11
Est. Completion 2026-07
Phase Phase 2

Sponsor

Baylor College of Medicine

616 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05355272

The ClinicalTrials.gov registry entry for NCT05355272 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (85% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gulf War Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Recombinant human growth hormone is the first listed.

NCT05355272 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT05355272 about?

NCT05355272 is a clinical study titled "Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)". The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat i...

What is the current status of trial NCT05355272?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-03-11. Estimated completion is 2026-07.

What conditions does trial NCT05355272 study?

This clinical trial studies the following conditions: Gulf War Syndrome, Adult Growth Hormone Deficiency.

What interventions are being tested in trial NCT05355272?

The interventions under investigation include: Recombinant human growth hormone (DRUG).

Who is sponsoring clinical trial NCT05355272?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05355272 being conducted?

This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gulf War Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gulf War Syndrome

All registered trials for this condition

Adult Growth Hormone Deficiency

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.